Cargando…
Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease
With the increasing incidence and prevalence, Crohn’s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931310/ https://www.ncbi.nlm.nih.gov/pubmed/35309310 http://dx.doi.org/10.3389/fimmu.2022.865968 |
_version_ | 1784671230569218048 |
---|---|
author | Zhou, Zhou Zhang, Yinghui Yang, Xue Pan, Yan Li, Liangping Gao, Caiping He, Chong |
author_facet | Zhou, Zhou Zhang, Yinghui Yang, Xue Pan, Yan Li, Liangping Gao, Caiping He, Chong |
author_sort | Zhou, Zhou |
collection | PubMed |
description | With the increasing incidence and prevalence, Crohn’s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study, we enrolled a total of 144 patients with CD and 239 healthy controls were enrolled. Clinical characteristics and laboratory parameters of enrolled subjects were retrieved from the electronic medical record database of our hospital. Serum cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA). Mucosa expression levels of inflammatory agents were measured by quantitative RT-PCR (qRT-PCR). We identified two neutrophil-based indexes, the neutrophil-to-albumin ratio (NAR) and neutrophil-to-bilirubin ratio (NBR), both of which had not yet been explored in CD or UC. NAR and NBR were significantly increased in patients with CD compared to those in healthy controls, and both indexes showed significantly positive correlations with CD activity and inflammatory load. In note, NAR and NBR showed better performance than blood neutrophil percentage, serum albumin, or bilirubin alone in these scenarios. More importantly, both NAR and NBR discriminated CD patients who completely or partially responded to infliximab (IFX) induction therapy from those with primary non-response. Our observations suggest that NAR and NBR may serve as promising biomarkers in the diagnosis and prediction of response to IFX therapy in CD. |
format | Online Article Text |
id | pubmed-8931310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89313102022-03-19 Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease Zhou, Zhou Zhang, Yinghui Yang, Xue Pan, Yan Li, Liangping Gao, Caiping He, Chong Front Immunol Immunology With the increasing incidence and prevalence, Crohn’s disease (CD) has become one of the most challenging diseases in both diagnosis and treatment of gastroenterology. Evaluation of the disease activity and mucosal healing guides clinical decisions regarding subsequent therapy for CD. In this study, we enrolled a total of 144 patients with CD and 239 healthy controls were enrolled. Clinical characteristics and laboratory parameters of enrolled subjects were retrieved from the electronic medical record database of our hospital. Serum cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA). Mucosa expression levels of inflammatory agents were measured by quantitative RT-PCR (qRT-PCR). We identified two neutrophil-based indexes, the neutrophil-to-albumin ratio (NAR) and neutrophil-to-bilirubin ratio (NBR), both of which had not yet been explored in CD or UC. NAR and NBR were significantly increased in patients with CD compared to those in healthy controls, and both indexes showed significantly positive correlations with CD activity and inflammatory load. In note, NAR and NBR showed better performance than blood neutrophil percentage, serum albumin, or bilirubin alone in these scenarios. More importantly, both NAR and NBR discriminated CD patients who completely or partially responded to infliximab (IFX) induction therapy from those with primary non-response. Our observations suggest that NAR and NBR may serve as promising biomarkers in the diagnosis and prediction of response to IFX therapy in CD. Frontiers Media S.A. 2022-03-04 /pmc/articles/PMC8931310/ /pubmed/35309310 http://dx.doi.org/10.3389/fimmu.2022.865968 Text en Copyright © 2022 Zhou, Zhang, Yang, Pan, Li, Gao and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhou, Zhou Zhang, Yinghui Yang, Xue Pan, Yan Li, Liangping Gao, Caiping He, Chong Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease |
title | Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease |
title_full | Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease |
title_fullStr | Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease |
title_full_unstemmed | Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease |
title_short | Clinical Significance of Novel Neutrophil-Based Biomarkers in the Diagnosis and Prediction of Response to Infliximab Therapy in Crohn’s Disease |
title_sort | clinical significance of novel neutrophil-based biomarkers in the diagnosis and prediction of response to infliximab therapy in crohn’s disease |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931310/ https://www.ncbi.nlm.nih.gov/pubmed/35309310 http://dx.doi.org/10.3389/fimmu.2022.865968 |
work_keys_str_mv | AT zhouzhou clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease AT zhangyinghui clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease AT yangxue clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease AT panyan clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease AT liliangping clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease AT gaocaiping clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease AT hechong clinicalsignificanceofnovelneutrophilbasedbiomarkersinthediagnosisandpredictionofresponsetoinfliximabtherapyincrohnsdisease |